Ta Chiang Liu

Summary

Publications

  1. ncbi request reprint Viruses with deletions in antiapoptotic genes as potential oncolytic agents
    Ta Chiang Liu
    Molecular Neurosurgery Laboratory, Massachusetts General Hospital and Harvard Medical School, MA, USA
    Oncogene 24:6069-79. 2005
  2. pmc Trichostatin A and oncolytic HSV combination therapy shows enhanced antitumoral and antiangiogenic effects
    Ta Chiang Liu
    Molecular Neurosurgery Laboratory, Brain Tumor Research Center, Department of Neurosurgery, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, USA
    Mol Ther 16:1041-7. 2008
  3. ncbi request reprint Herpes simplex virus Us3(-) mutant as oncolytic strategy and synergizes with phosphatidylinositol 3-kinase-Akt targeting molecular therapeutics
    Ta Chiang Liu
    Molecular Neurosurgery Laboratory, Brain Tumor Research Center, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, USA
    Clin Cancer Res 13:5897-902. 2007
  4. ncbi request reprint Dominant-negative fibroblast growth factor receptor expression enhances antitumoral potency of oncolytic herpes simplex virus in neural tumors
    Ta Chiang Liu
    Molecular Neurosurgery Laboratory, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, USA
    Clin Cancer Res 12:6791-9. 2006
  5. ncbi request reprint Oncolytic HSV armed with platelet factor 4, an antiangiogenic agent, shows enhanced efficacy
    Ta Chiang Liu
    Molecular Neurosurgery Laboratory, Massachusetts General Hospital and Harvard Medical School, CPZN 3800 Simches Research Building, 185 Cambridge Street, Boston, MA 02114, USA
    Mol Ther 14:789-97. 2006
  6. pmc Hypoxia enhances the replication of oncolytic herpes simplex virus
    Manish K Aghi
    Department of Neurosurgery, University of California, San Francisco, California 94143 01112, USA
    Mol Ther 17:51-6. 2009
  7. doi request reprint Oncolytic adenoviruses for cancer gene therapy
    Ta Chiang Liu
    Brain Tumor Research Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA
    Methods Mol Biol 433:243-58. 2008
  8. ncbi request reprint Systemic efficacy with oncolytic virus therapeutics: clinical proof-of-concept and future directions
    Ta Chiang Liu
    Brain Tumor Research Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA
    Cancer Res 67:429-32. 2007
  9. pmc Human glioblastoma-derived cancer stem cells: establishment of invasive glioma models and treatment with oncolytic herpes simplex virus vectors
    Hiroaki Wakimoto
    Molecular Neurosurgery Laboratory, Brain Tumor Research Center, Department of Neurosurgery, Massachusetts General Hospital, Boston, MA 02114, USA
    Cancer Res 69:3472-81. 2009
  10. ncbi request reprint An E1B-19 kDa gene deletion mutant adenovirus demonstrates tumor necrosis factor-enhanced cancer selectivity and enhanced oncolytic potency
    Ta Chiang Liu
    Viral and Genetic Therapy Program, Cancer Research UK, Imperial College Faculty of Medicine, London, UK
    Mol Ther 9:786-803. 2004

Collaborators

Detail Information

Publications17

  1. ncbi request reprint Viruses with deletions in antiapoptotic genes as potential oncolytic agents
    Ta Chiang Liu
    Molecular Neurosurgery Laboratory, Massachusetts General Hospital and Harvard Medical School, MA, USA
    Oncogene 24:6069-79. 2005
    ..In this review, we summarize the recent development of this concept, the potential obstacles, and future directions for optimization...
  2. pmc Trichostatin A and oncolytic HSV combination therapy shows enhanced antitumoral and antiangiogenic effects
    Ta Chiang Liu
    Molecular Neurosurgery Laboratory, Brain Tumor Research Center, Department of Neurosurgery, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, USA
    Mol Ther 16:1041-7. 2008
    ..Therefore, combination treatment with TSA and oncolytic HSV provides a novel approach to cancer therapy...
  3. ncbi request reprint Herpes simplex virus Us3(-) mutant as oncolytic strategy and synergizes with phosphatidylinositol 3-kinase-Akt targeting molecular therapeutics
    Ta Chiang Liu
    Molecular Neurosurgery Laboratory, Brain Tumor Research Center, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, USA
    Clin Cancer Res 13:5897-902. 2007
    ..We hypothesized that Us3 mutants, whose replication would be inhibited by apoptosis in normal cells, would be selective for tumor cells...
  4. ncbi request reprint Dominant-negative fibroblast growth factor receptor expression enhances antitumoral potency of oncolytic herpes simplex virus in neural tumors
    Ta Chiang Liu
    Molecular Neurosurgery Laboratory, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, USA
    Clin Cancer Res 12:6791-9. 2006
    ..Here, we examine the strategy of arming oncolytic HSV with a dominant-negative FGF receptor (dnFGFR) that targets the FGF signaling pathway...
  5. ncbi request reprint Oncolytic HSV armed with platelet factor 4, an antiangiogenic agent, shows enhanced efficacy
    Ta Chiang Liu
    Molecular Neurosurgery Laboratory, Massachusetts General Hospital and Harvard Medical School, CPZN 3800 Simches Research Building, 185 Cambridge Street, Boston, MA 02114, USA
    Mol Ther 14:789-97. 2006
    ..Enhancing the antiangiogenic properties of oncolytic HSV through the expression of antiangiogenic factors such as PF4 is a powerful new strategy that targets both the tumor cells and tumor vasculature...
  6. pmc Hypoxia enhances the replication of oncolytic herpes simplex virus
    Manish K Aghi
    Department of Neurosurgery, University of California, San Francisco, California 94143 01112, USA
    Mol Ther 17:51-6. 2009
    ....
  7. doi request reprint Oncolytic adenoviruses for cancer gene therapy
    Ta Chiang Liu
    Brain Tumor Research Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA
    Methods Mol Biol 433:243-58. 2008
    ..Using adenovirus as a template, this chapter describes common assays used for the study of oncolytic viruses, with special emphasis on in vitro and in vivo viral replication determination...
  8. ncbi request reprint Systemic efficacy with oncolytic virus therapeutics: clinical proof-of-concept and future directions
    Ta Chiang Liu
    Brain Tumor Research Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA
    Cancer Res 67:429-32. 2007
    ..Further directions for optimizing i.v. delivery and efficacy are discussed...
  9. pmc Human glioblastoma-derived cancer stem cells: establishment of invasive glioma models and treatment with oncolytic herpes simplex virus vectors
    Hiroaki Wakimoto
    Molecular Neurosurgery Laboratory, Brain Tumor Research Center, Department of Neurosurgery, Massachusetts General Hospital, Boston, MA 02114, USA
    Cancer Res 69:3472-81. 2009
    ..This is important for designing new oHSV vectors and clinical trials. Moreover, the new glioma models described in this study provide powerful tools for testing experimental therapeutics and studying invasion and angiogenesis...
  10. ncbi request reprint An E1B-19 kDa gene deletion mutant adenovirus demonstrates tumor necrosis factor-enhanced cancer selectivity and enhanced oncolytic potency
    Ta Chiang Liu
    Viral and Genetic Therapy Program, Cancer Research UK, Imperial College Faculty of Medicine, London, UK
    Mol Ther 9:786-803. 2004
    ..E1B-19 kDa deletion should be considered as a feature of oncolytic adenoviruses to enhance their safety, spread, and efficacy...
  11. ncbi request reprint Development of targeted oncolytic virotherapeutics through translational research
    Ta Chiang Liu
    Jennerex Biotherapeutics, One Market Street, Spear Tower, Suite 2260, San Francisco, CA 94105, USA
    Expert Opin Biol Ther 8:1381-91. 2008
    ..The key to success is integration of bidirectional translational research to rapidly address issues encountered in the laboratory and the clinics...
  12. doi request reprint The targeted oncolytic poxvirus JX-594 demonstrates antitumoral, antivascular, and anti-HBV activities in patients with hepatocellular carcinoma
    Ta Chiang Liu
    Jennerex Biotherapeutics, San Francisco, California 94105, USA
    Mol Ther 16:1637-42. 2008
    ..JX-594 treatment in HBV-associated HCC warrants further clinical testing; a Phase II trial is underway...
  13. doi request reprint Translation of targeted oncolytic virotherapeutics from the lab into the clinic, and back again: a high-value iterative loop
    Ta Chiang Liu
    1Jennerex Biotherapeutics, San Francisco, California, USA
    Mol Ther 16:1006-8. 2008
  14. doi request reprint Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial
    Byeong Ho Park
    Dong A University College of Medicine, Busan, South Korea
    Lancet Oncol 9:533-42. 2008
    ..We aimed to assess intratumoral injection of JX-594 in patients with refractory primary or metastatic liver cancer...
  15. ncbi request reprint Targeting the untargetable: oncolytic virotherapy for the cancer stem cell
    Ta Chiang Liu
    Jennerex Biotherapeutics, Inc, San Francisco, California 94105, USA
    Mol Ther 15:2060-1. 2007
  16. ncbi request reprint Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress
    Ta Chiang Liu
    Jennerex Biotherapeutics, One Market Street, Spear Tower, Suite 2260, San Francisco, CA 94105, USA
    Nat Clin Pract Oncol 4:101-17. 2007
    ..Systemic safety and efficiacy has been clearly demonstrated with some virotherapeutics. The implications of these data for future virotherapy development are discussed...
  17. ncbi request reprint E3 gene manipulations affect oncolytic adenovirus activity in immunocompetent tumor models
    Yaohe Wang
    Viral and Genetic Therapy Program, Cancer Research UK and Imperial College School of Medicine, Hammersmith Hospital, London, UK
    Nat Biotechnol 21:1328-35. 2003
    ..E3-dependent differences were not evident in athymic mice. These findings have important implications for the design of oncolytic adenoviruses and may explain the rapid clearance of E3-10.4/14.5,14.7-deleted adenoviruses in patients...